U. Hasler-Strub

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

P. Neven, K. Zaman, R. Winterhalder, 2015, European journal of cancer.

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

J. Bernhard, K. Zaman, R. Winterhalder, 2016, BMC Cancer.

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial

J. Bernhard, M. Regan, U. Hasler-Strub, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis.

U. Hasler-Strub, D. Ackermann, P. Jaeger, 1997, Nephrology, Dialysis and Transplantation.

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].

U. Hasler-Strub, C. Rochlitz, A. Mueller, 2022, Journal of geriatric oncology.

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer

K. Zaman, R. Winterhalder, C. Mamot, 2023, Scientific Reports.

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

J. Bernhard, K. Zaman, R. Winterhalder, 2016, BMC Cancer.

Metabolic evaluation of patients with recurrent idiopathic calcium nephrolithiasis.

U. Hasler-Strub, Bernhard J. M. Hess, Daniel Ackermann, 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.

K. Zaman, R. Winterhalder, U. Hasler-Strub, 2014 .

Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08.

P. Neven, K. Zaman, R. Winterhalder, 2015, European journal of cancer.